NASDAQ:REXN Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free REXN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.81▼$2.2452-Week Range N/AVolume2,579 shsAverage Volume162,968 shsMarket Capitalization$8.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Rexahn Pharmaceuticals alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story REXN Stock News HeadlinesFebruary 16, 2024 | morningstar.comAurinia Pharmaceuticals Inc AUPHMarch 27, 2023 | benzinga.comMaxCyte Appoints Douglas Swirsky as Chief Financial OfficerApril 18, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereJanuary 1, 2023 | thestreet.comRexahn: Holes Galore in Serdaxin DataSee More Headlines Receive REXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2019Today4/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:REXN CUSIPN/A CIK1228627 Webwww.rexahn.com Phone(248) 681-9815FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.60% Return on Assets-55.68% Debt Debt-to-Equity RatioN/A Current Ratio3.37 Quick Ratio3.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / BookN/AMiscellaneous Outstanding Shares4,483,000Free FloatN/AMarket Cap$8.11 million OptionableOptionable Beta0.98 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMina Patel SoochPresident, Chief Executive Officer & DirectorBernhard HoffmannVice President-Corporate Development & OperationsAmy RabournChief Accounting Officer & Vice President-FinanceKonstantinos CharizanisSenior Director-Market Strategy, R&DDrey ColemanDirector-Clinical Operations & Vendor ManagementKey CompetitorsASLAN PharmaceuticalsNASDAQ:ASLNClever LeavesNASDAQ:CLVRObsEvaNASDAQ:OBSVTFF PharmaceuticalsNASDAQ:TFFPLixte BiotechnologyNASDAQ:LIXTView All Competitors REXN Stock Analysis - Frequently Asked Questions How were Rexahn Pharmaceuticals' earnings last quarter? Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.34. When did Rexahn Pharmaceuticals' stock split? Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Rexahn Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Imunon (CLSN), LadRx (CYTR) and SCYNEXIS (SCYX). This page (NASDAQ:REXN) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rexahn Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.